Xtant Medical (NYSEAMERICAN:XTNT) Releases Earnings Results, Misses Estimates By $0.05 EPS

Xtant Medical (NYSEAMERICAN:XTNT) released its earnings results on Tuesday. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05), FiscalAI reports. The firm had revenue of $23.03 million during the quarter, compared to the consensus estimate of $24.88 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Xtant Medical Stock Performance

Shares of XTNT stock opened at $0.45 on Tuesday. The company has a market capitalization of $62.56 million, a price-to-earnings ratio of 44.64 and a beta of -0.13. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.64 and a current ratio of 3.34. Xtant Medical has a 52 week low of $0.39 and a 52 week high of $0.95. The company has a 50-day simple moving average of $0.44 and a 200 day simple moving average of $0.51.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a “buy” rating and set a $1.00 price objective on shares of Xtant Medical in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $1.00.

Institutional Investors Weigh In On Xtant Medical

Institutional investors have recently made changes to their positions in the stock. Wiregrass Investment Management LLC acquired a new stake in shares of Xtant Medical during the 4th quarter worth approximately $81,000. Renaissance Technologies LLC raised its holdings in shares of Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after buying an additional 205,945 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the last quarter. Finally, Mink Brook Asset Management LLC boosted its stake in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.